Original Article

You have full text access to this OnlineOpen article

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

  1. Lyndsay Harris M.D.1,2,†,*,
  2. Gerald Batist M.D.3,
  3. Robert Belt M.D.4,
  4. Douglas Rovira M.D.5,
  5. Rudolph Navari M.D.6,
  6. Nozar Azarnia Ph.D.7,‡,
  7. Lauri Welles M.D.8,§,
  8. Eric Winer M.D.1,2,¶,
  9. TLC D-99 Study Group ‖

Article first published online: 28 DEC 2001

DOI: 10.1002/cncr.10201

Issue

Cancer

Cancer

Volume 94, Issue 1, pages 25–36, 1 January 2002

Additional Information

How to Cite

Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E. and TLC D-99 Study Group (2002), Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94: 25–36. doi: 10.1002/cncr.10201

Author Information

  1. 1

    Duke University Medical Center, Durham, North Carolina

  2. 2

    Dana-Farber Cancer Institute, Boston, Massachusetts

  3. 3

    McGill University, Montreal, Quebec, Canada

  4. 4

    St. Luke's Hospital, Kansas City, Missouri

  5. 5

    University of Colorado, Denver, Colorado

  6. 6

    Simon Williamson Clinic, Birmingham, Alabama

  7. 7

    Columbia Presbyterian Medical Center, New York, New York

  8. 8

    Elan Pharmaceuticals, Princeton, New Jersey

  1. †

    Fax: (617) 632-3709

  2. ‡

    Dr. Nozar Azarnia is a consultant for Elan Corporation.

  3. §

    Lauri Welles is an employee of Elan Pharmaceuticals.

  4. Eric Winer was a consultant to the Liposome Company in 1999 during the course of their submission of TLD to the FDA.

  5. ‖

    The following investigators and their institutions also participated in the study: Thomas Garrett, Columbia-Presbyterian Medical Center, New York, NY; Douglas Blayney, Lewis Cancer Care Center, Pomona, CA; Laurence Elias, UNM Cancer Center, Albuquerque, NM; Joanne Mortimer, Barnard Cancer Center, St. Louis, MO; Burton Needles, Saint John's Mercy Medical Center, St. Louis, MO; Timothy Webb, Central Arkansas Oncology Clinic, Hot Springs, AR; Joshua Atiba, UC Irvine Medical Center, Orange, CA; John Bickers, LSU Medical Center, New Orleans, LA; Thomas Godfrey, Loma Linda University Medical Center, Loma Linda, CA; Richard Love, University of Wisconsin Hospital, Madison, WI; Dustan Osborn, Western Washington Cancer Center, Olympia, WA; Joseph Aisner, University of Maryland Cancer Center, Baltimore, MD; Tom Anderson, Froedtert Memorial Lutheran Hosp, Milwaukee, WI; Dean Butler, Dial Research Associates, Nashville, TN; Paul Calabresi, Rhode Island Hospital, Providence, RI; Lawrence Feldman, Mount Sinai Hospital, Chicago, IL; Robert Kerr, Southwest Regional Cancer Centers, Austin, TX; Hans Nevinny, Memorial Medical Center, Tulsa, OK; Craig Reynolds, Ocala Oncology Center, Ocala, FL; Andrew Schneider, Hematology and Medical Oncology, Lauderhill, FL; Charles Tweedy, Amos Community Cancer Center, Columbus, GA; William Whaley, West Paces Ferry Clinic, Atlanta, GA; Michael DeMattia, Mount Clemons Hospital, Mount Clemons, MI; Gregory Harper, Lehigh Valley Hospital, Allentown, PA; Rebecca Moroose, Walt Disney Memorial Cancer Institute, Orlando, FL; Harry Staszewski, Winthrop University Hospital, Mineola, NY; Albert Begas, Boca Raton Community Hospital, Boca Raton, FL; Janice Dutcher, Montefiore Medical Center, Bronx, NY; Robert Ellis, Madigan Army Medical Center, Tacoma, WA; Gini Fleming, University of Chicago Medical Center, Chicago, IL; Michael Garcia, Norwood Clinic Research Center, Birmingham, AL; Joel Granick, Midwestern Regional Medical Center, Zion, IL; Jonathan Kloss, Lourdes Hospital Cancer Center, Binghamton, NY; Michael Roberts, Hematology and Oncology Associates, Phoenix, AZ; Federico Sanchez, Cancer Care Center, Menomonee Falls, WI; Richard Silver, New York Hospital–Cornell Medical Center, New York; Harvey Taylor, Hodges Cancer Center, Lubbock, TX.

*Dana-Farber Cancer Institute, Room D1210, 44 Binney Street, Boston, MA 02115

Publication History

  1. Issue published online: 28 DEC 2001
  2. Article first published online: 28 DEC 2001
  3. Manuscript Accepted: 17 AUG 2001
  4. Manuscript Received: 1 JUN 2001

Funded by

  • Elan Pharmaceuticals, Princeton, New Jersey

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (139K)

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Meena Mahmood, Dan Casciano, Yang Xu, Alexandru S. Biris, Engineered nanostructural materials for application in cancer biology and medicine, Journal of Applied Toxicology, 2012, 32, 1
    Direct Link:
  2. 2
    Patrizia Vici, Giuseppe Colucci, Francesco Giotta, Domenico Sergi, Gianfranco Filippelli, Pasquale Perri, Claudio Botti, Enrico Vizza, Armando Carpino, Laura Pizzuti, Agnese Latorre, Diana Giannarelli, Massimo Lopez, Luigi Di Lauro, A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study, Journal of Experimental & Clinical Cancer Research, 2011, 30, 1, 39

    CrossRef

  3. 3
    D. Amadori, C. Milandri, G. Comella, S. Saracchini, S. Salvagni, C. Barone, R. Bordonaro, V. Gebbia, A. Barbato, P. Serra, D. Gattuso, O. Nanni, B. Baconnet, G. Gasparini, A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer, European Journal of Cancer, 2011, 47, 14, 2091

    CrossRef

  4. 4
    Alessandra Gennari, Mauro D'Amico, Anthracyclines in the management of metastatic breast cancer: state of the art, European Journal of Cancer Supplements, 2011, 9, 2, 11

    CrossRef

  5. 5
    Elżbieta Senkus, Jacek Jassem, Cardiovascular effects of systemic cancer treatment, Cancer Treatment Reviews, 2011, 37, 4, 300

    CrossRef

  6. 6
    Alessandra Gennari, Elisabetta Pietri, Dino Amadori, Case histories: breast cancer, European Journal of Cancer Supplements, 2011, 9, 2, 36

    CrossRef

  7. 7
    Serena Di Cosimo, Heart to heart with trastuzumab: a review on cardiac toxicity, Targeted Oncology, 2011, 6, 4, 189

    CrossRef

  8. 8
    Juan C. Plana, La quimioterapia y el corazón, Revista Española de Cardiología, 2011, 64, 5, 409

    CrossRef

  9. 9
    E. Curtit, P. Nouyrigat, N. Dohollou, E. Levy, A. Lortholary, J. Gligorov, T. Facchini, D. Jaubert, N. Maille, X. Pivot, V. Grangé, L. Cals, Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines, European Journal of Cancer, 2011, 47, 16, 2396

    CrossRef

  10. 10
    Cristina Riggio, Eleonora Pagni, Vittoria Raffa, Alfred Cuschieri, Nano-Oncology: Clinical Application for Cancer Therapy and Future Perspectives, Journal of Nanomaterials, 2011, 2011, 1

    CrossRef

  11. 11
    Heloisa Sawaya, Juan Carlos Plana, Marielle Scherrer-Crosbie, Newest Echocardiographic Techniques for the Detection of Cardiotoxicity and Heart Failure During Chemotherapy, Heart Failure Clinics, 2011, 7, 3, 313

    CrossRef

  12. 12
    Matteo Dell'olio, Rosario Potito scalzulli, Grazia Sanpaolo, Michele Nobile, Francesco Saverio mantuano, Antonio La sala, Giovanni D'arena, Eustachio Miraglia, Anna Lucania, Lucia Mastrullo, Cascavilla Nicola, Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma, Leukemia & Lymphoma, 2011, 52, 7, 1222

    CrossRef

  13. 13
    T. Melchardt, S. W. Hofbauer, R. Greil, G. Hopfinger, Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010, memo - Magazine of European Medical Oncology, 2011, 4, 2, 120

    CrossRef

  14. 14
    Alessia Di Legge, Ilaria Nausica Trivellizzi, Maria Cristina Moruzzi, Adele Pesce, Giovanni Scambia, Domenica Lorusso, Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer, International Journal of Gynecological Cancer, 2011, 21, 8, 1446

    CrossRef

  15. 15
    Veronika Hanušová, Iva Boušová, Lenka Skálová, Possibilities to increase the effectiveness of doxorubicin in cancer cells killing, Drug Metabolism Reviews, 2011, 43, 4, 540

    CrossRef

  16. 16
    Christian Johannes Schmitt, Sascha Dietrich, Antony Dick Ho, Mathias Witzens-Harig, Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors, Annals of Hematology, 2011,

    CrossRef

  17. 17
    Matti Aapro, SIOG (International Society of Geriatric Oncology) and anthracycline use in the elderly, European Journal of Cancer Supplements, 2011, 9, 2, 30

    CrossRef

  18. 18
    M. Venturini, C. Bighin, F. Puglisi, N. Olmeo, E. Aitini, G. Colucci, O. Garrone, A. Paccagnella, G. Marini, L. Crinò, M. Mansutti, B. Baconnet, A. Barbato, L. Del Mastro, A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer, The Breast, 2010, 19, 5, 333

    CrossRef

  19. 19
    Tamás Nagykálnai, A nem pegilált liposzomális doxorubicin (Myocet®), mint a szabad doxorubicin kevésbé kardiotoxikus alternatívája, Magyar Onkológia, 2010, 54, 4, 359

    CrossRef

  20. 20
    M. Aapro, C. Bernard-Marty, E. G. C. Brain, G. Batist, F. Erdkamp, K. Krzemieniecki, R. Leonard, A. Lluch, S. Monfardini, M. Ryberg, P. Soubeyran, U. Wedding, Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper, Annals of Oncology, 2010, 22, 2, 257

    CrossRef

  21. 21
    Joy M. Fulbright, Winston Huh, Pete Anderson, Joya Chandra, Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?, Current Oncology Reports, 2010, 12, 6, 411

    CrossRef

  22. 22
    Manabu Minami, Shigemi Matsumoto, Hisanori Horiuchi, Cardiovascular Side-Effects of Modern Cancer Therapy, Circulation Journal, 2010, 74, 9, 1779

    CrossRef

  23. 23
    Claudia Andreetta, Alessandro M. Minisini, Manuela Miscoria, Fabio Puglisi, First-line chemotherapy with or without biologic agents for metastatic breast cancer, Critical Reviews in Oncology/Hematology, 2010, 76, 2, 99

    CrossRef

  24. 24
    Twan Lammers, Vladimir Subr, Karel Ulbrich, Peter Peschke, Peter E Huber, Wim E Hennink, Gert Storm, Fabian Kiessling, HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations, Nanomedicine, 2010, 5, 10, 1501

    CrossRef

  25. 25
    Yiguang Wang, Xiuli Wei, Chunling Zhang, Fayun Zhang, Wei Liang, Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects, Therapeutic Delivery, 2010, 1, 2, 273

    CrossRef

  26. 26
    A. Anton, A. Ruiz, A. Plazaola, L. Calvo, M. A. Segui, A. Santaballa, M. Munoz, P. Sanchez, A. Miguel, E. Carrasco, J. Lao, J. Camps, J. Alfaro, S. Antolin, M. C. Camara, Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study, Annals of Oncology, 2010, 22, 1, 74

    CrossRef

  27. 27
    Carlo Palmieri, Jonathan Krell, Colin R. James, Catherine Harper-Wynne, Vivek Misra, Susan Cleator, David Miles, Rechallenging with anthracyclines and taxanes in metastatic breast cancer, Nature Reviews Clinical Oncology, 2010, 7, 10, 561

    CrossRef

  28. 28
    Antonella Fontana, Maurizio Viale, Susanna Guernelli, Carla Gasbarri, Egon Rizzato, Massimo Maccagno, Giovanni Petrillo, Cinzia Aiello, Silvano Ferrini, Domenico Spinelli, Strategies for improving the water solubility of new antitumour nitronaphthylbutadiene derivatives, Organic & Biomolecular Chemistry, 2010, 8, 24, 5674

    CrossRef

  29. 29
    S. Guiu, I. Adoubi, J. C. Kouassi Comoe, P. Fumoleau, B. Coudert, Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif, Journal Africain du Cancer / African Journal of Cancer, 2010, 3, 2, 128

    CrossRef

  30. 30
    Margarita Majem, Ramon Salazar, Margarita Garcia, Ana Clopes, Carme Muñoz, Beatriz Pardo, Marisa Martinez, Carmen Cuadra, Ana Montes, Ricard Mis, Claudio Savulsky, Josep Ramon Germa-Lluch, A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors, Journal of Liposome Research, 2009, 19, 4, 261

    CrossRef

  31. 31
    Andrea Rocca, Roberta Maltoni, Alessandro Passardi, Ilaria Massa, Michele Aquilina, Ruggero Ridolfi, Toni Ibrahim, Lorenzo Cecconetto, Samanta Sarti, Elisabetta Pietri, Oriana Nanni, Dino Amadori, A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer, Cancer Chemotherapy and Pharmacology, 2009, 65, 5, 871

    CrossRef

  32. 32
    Marzia Lotrionte, Giovanni Palazzoni, Rosaria Natali, Gianluca Comerci, Antonio Abbate, Silvia Di Persio, Giuseppe G.L. Biondi-Zoccai, Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points, International Journal of Cardiology, 2009, 135, 1, 72

    CrossRef

  33. 33
      Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG), Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis, British Journal of Haematology, 2009, 145, 3
    Direct Link:
  34. 34
    P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, M. W. Verrill, Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk, Annals of Oncology, 2009, 20, 5, 816

    CrossRef

  35. 35
    R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros, Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocetâ„¢), The Breast, 2009, 18, 4, 218

    CrossRef

  36. 36
    Giuseppe Visani, Alessandro Isidori, Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin’s lymphoma: where we stand, Expert Review of Anticancer Therapy, 2009, 9, 3, 357

    CrossRef

  37. 37
    Elmar Stickeler, Maximilian Klar, Dirk Watermann, Annette Geibel, Martha Földi, Annette Hasenburg, Gerald Gitsch, Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial, Breast Cancer Research and Treatment, 2009, 117, 3, 591

    CrossRef

  38. 38
    S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, S. Van Belle, C. Vogel, N. Wilcken, C. Wiltschke, C. C. Zielinski, H. Zwierzina, Third consensus on medical treatment of metastatic breast cancer, Annals of Oncology, 2009, 20, 11, 1771

    CrossRef

  39. 39
    Davinder S. Jassal, Song-Yee Han, Cecilia Hans, Anita Sharma, Tielan Fang, Roien Ahmadie, Matthew Lytwyn, Jonathan R. Walker, Raveen S. Bhalla, Andrew Czarnecki, Tarek Moussa, Pawan K. Singal, Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy, Journal of the American Society of Echocardiography, 2009, 22, 4, 418

    CrossRef

  40. 40
    D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, T. Suter, Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies, Annals of Oncology, 2008, 19, 9, 1530

    CrossRef

  41. 41
    Andrew Z Wang, Frank Gu, Liangfang Zhang, Juliana M Chan, Aleksander Radovic-Moreno, Mariam R Shaikh, Omid C Farokhzad, Biofunctionalized targeted nanoparticles for therapeutic applications, Expert Opinion on Biological Therapy, 2008, 8, 8, 1063

    CrossRef

  42. 42
    Y. YILDIRIM, E. GULTEKIN, M.E. AVCI, M.M. INAL, S. YUNUS, S. TINAR, Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer, International Journal of Gynecological Cancer, 2008, 18, 2
    Direct Link:
  43. 43
    María Sereno, Antonella Brunello, Alberto Chiappori, Jorge Barriuso, Enrique Casado, Cristóbal Belda, Javier Castro, Jaime Feliu, Manuel González-Barón, Cardiac toxicity: old and new issues in anti-cancer drugs, Clinical and Translational Oncology, 2008, 10, 1, 35

    CrossRef

  44. 44
    Tong-Hsien Chow, Yi-Yu Lin, Jeng-Jong Hwang, Hsin-Ell Wang, Yun-Long Tseng, Victor Fei Pang, Shyh-Jen Wang, Jacqueline Whang-Peng, Gann Ting, Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model, Nuclear Medicine and Biology, 2008, 35, 5, 623

    CrossRef

  45. 45
    Flora Stavridi, Carlo Palmieri, Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer, Expert Review of Anticancer Therapy, 2008, 8, 12, 1859

    CrossRef

  46. 46
    Chien-Ho CHEN, Der-Zen LIU, Hsu-Wei FANG, Hong-Jen LIANG, Tzu-Sheng YANG, Shyr-Yi LIN, Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer, Bioscience, Biotechnology, and Biochemistry, 2008, 72, 6, 1586

    CrossRef

  47. 47
    Lionel Apetoh, Grégoire Mignot, Theocharis Panaretakis, Guido Kroemer, Laurence Zitvogel, Immunogenicity of anthracyclines: moving towards more personalized medicine, Trends in Molecular Medicine, 2008, 14, 4, 141

    CrossRef

  48. 48
    Marianne Labussière, Alice Aarnink, Sophie Pinel, Luc Taillandier, Jean-Marie Escanyé, Muriel Barberi-Heyob, Valérie Bernier-Chastagner, François Plénat, Pascal Chastagner, Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts, Anti-Cancer Drugs, 2008, 19, 10, 991

    CrossRef

  49. 49
    Peter Schmid, J. Krocker, R. Kreienberg, P. Klare, K. Kittel, H. Sommer, G. Heinrich, T. Steck, W. Lichtenegger, D. Elling, S. Kümmel, Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial, Cancer Chemotherapy and Pharmacology, 2008, 64, 2, 401

    CrossRef

  50. 50
    S. Barco, R. Colomer, L. Calvo, I. Tusquets, E. Adrover, P. Sánchez, J. Rifà, J. Haba, J. A. Virizuela, Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial, Breast Cancer Research and Treatment, 2008, 116, 2, 351

    CrossRef

  51. 51
    Alessandro M Minisini, Claudia Andreetta, Gianpiero Fasola, Fabio Puglisi, Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer, Expert Review of Anticancer Therapy, 2008, 8, 3, 331

    CrossRef

  52. 52
    A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, L. Fernandez, Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study, Annals of Oncology, 2008, 20, 3, 454

    CrossRef

  53. 53
    Brent Anderson, Douglas B Sawyer, Predicting and preventing the cardiotoxicity of cancer therapy, Expert Review of Cardiovascular Therapy, 2008, 6, 7, 1023

    CrossRef

  54. 54
    Surabhi Amar, Vivek Roy, Edith A. Perez, Treatment of metastatic breast cancer: looking towards the future, Breast Cancer Research and Treatment, 2008, 114, 3, 413

    CrossRef

  55. 55
    T Lammers, W E Hennink, G Storm, Tumour-targeted nanomedicines: principles and practice, British Journal of Cancer, 2008, 99, 3, 392

    CrossRef

  56. 56
    Antonia Busse, Gero Hütter, Jan Michael Siehl, Alexander Schmittel, Eckhard Thiel, Ulrich Keilholz, A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma, Leukemia & Lymphoma, 2007, 48, 9, 1755

    CrossRef

  57. 57
    Elly Barry, Jorge A Alvarez, Rebecca E Scully, Tracie L Miller, Steven E Lipshultz, Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management, Expert Opinion on Pharmacotherapy, 2007, 8, 8, 1039

    CrossRef

  58. 58
    Gerald Batist, Cardiac safety of liposomal anthracyclines, Cardiovascular Toxicology, 2007, 7, 2, 72

    CrossRef

  59. 59
    M Shehata, A Mukherjee, R Sharma, S Chan, Liposomal doxorubicin in breast cancer, Women's Health, 2007, 3, 5, 557

    CrossRef

  60. 60
    S. Dean Allison, Liposomal Drug Delivery, Journal of Infusion Nursing, 2007, 30, 2, 89

    CrossRef

  61. 61
    R. ANGIOLI, I. PALAIA, M. CALCAGNO, N. MANCI, M.A. ZULLO, F. BELLATI, G. PERNIOLA, A. DE VIVO, P. BENEDETTI PANICI, Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies, International Journal of Gynecological Cancer, 2007, 17, 1
    Direct Link:
  62. 62
    Luigi Rigacci, Silvia Mappa, Luca Nassi, Renato Alterini, Valentina Carrai, Franco Bernardi, Alberto Bosi, Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines, Hematological Oncology, 2007, 25, 4
    Direct Link:
  63. 63
    Raymond Ng, Michael D Green, Managing cardiotoxicity in anthracycline-treated breast cancers, Expert Opinion on Drug Safety, 2007, 6, 3, 315

    CrossRef

  64. 64
    Sabine Wagner, Ove Peters, Christin Fels, Gisela Janssen, Anne-Kathrin Liebeskind, Axel Sauerbrey, Meinolf Suttorp, Peter Hau, Johannes E. A. Wolff, Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors, Journal of Neuro-Oncology, 2007, 86, 2, 175

    CrossRef

  65. 65
    Raymond Ng, Nathan Better, Michael D. Green, Anticancer Agents and Cardiotoxicity, Seminars in Oncology, 2006, 33, 1, 2

    CrossRef

  66. 66
    Gerald Batist, Lyndsay Harris, Nozar Azarnia, Lily Waiyee Lee, Pascual Daza-Ramirez, Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis, Anti-Cancer Drugs, 2006, 17, 5, 587

    CrossRef

  67. 67
    Hanako Kobayashi, P Charles Lin, Nanotechnology for antiangiogenic cancer therapy, Nanomedicine, 2006, 1, 1, 17

    CrossRef

  68. 68
    Gunnar Myhr, Johan Moan, Synergistic and tumour selective effects of chemotherapy and ultrasound treatment, Cancer Letters, 2006, 232, 2, 206

    CrossRef

  69. 69
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  70. 70
    Hans Wildiers, Etienne G.C Brain, Adjuvant chemotherapy in elderly patients with breast cancer: where are we?, Current Opinion in Oncology, 2005, 17, 6, 566

    CrossRef

  71. 71
    B. Hazra, B. Kumar, S. Biswas, B.N. Pandey, K.P. Mishra, Enhancement of the tumour inhibitory activity, in vivo, of diospyrin, a plant-derived quinonoid, through liposomal encapsulation, Toxicology Letters, 2005, 157, 2, 109

    CrossRef

  72. 72
    L Eikenes, M Tari, I Tufto, Ø S Bruland, C de Lange Davies, Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts, British Journal of Cancer, 2005, 93, 1, 81

    CrossRef

  73. 73
    Ralf-Dieter Hofheinz, Senta Ulrike Gnad-Vogt, Ulrich Beyer, Andreas Hochhaus, Liposomal encapsulated anti-cancer drugs, Anti-Cancer Drugs, 2005, 16, 7, 691

    CrossRef

  74. 74
    David C. Bibby, James E. Talmadge, Milind K. Dalal, Scott G. Kurz, Kevin M. Chytil, Stephen E. Barry, David G. Shand, Matthias Steiert, Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice, International Journal of Pharmaceutics, 2005, 293, 1-2, 281

    CrossRef

  75. 75
    Karlijn A. Wouters, Leontien C. M. Kremer, Tracie L. Miller, Eugene H. Herman, Steven E. Lipshultz, Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies, British Journal of Haematology, 2005, 131, 5
    Direct Link:
  76. 76
    William J. Gradishar, The future of breast cancer: the role of prognostic factors, Breast Cancer Research and Treatment, 2005, 89, S1, S17

    CrossRef

  77. 77
    Athanasios Fassas, Achilles Anagnostopoulos, The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia, Leukemia & Lymphoma, 2005, 46, 6, 795

    CrossRef

  78. 78
    Karen Seiter, Toxicity of the topoisomerase II inhibitors, Expert Opinion on Drug Safety, 2005, 4, 2, 219

    CrossRef

  79. 79
    Theresa M. Allen, Francis J. Martin, Advantages of liposomal delivery systems for anthracyclines, Seminars in Oncology, 2004, 31, 5

    CrossRef

  80. 80
    Maria Theodoulou, Clifford Hudis, Cardiac profiles of liposomal anthracyclines, Cancer, 2004, 100, 10
    Direct Link:
  81. 81
    Michael S. Ewer, Francis J. Martin, I. Craig Henderson, Charles L. Shapiro, Robert S. Benjamin, Alberto A. Gabizon, Cardiac safety of liposomal anthracyclines, Seminars in Oncology, 2004, 31, 161

    CrossRef

  82. 82
    Robin L Jones, Gerald J Berry, Robert D Rubens, David W Miles, Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin, The Lancet Oncology, 2004, 5, 9, 575

    CrossRef

  83. 83
    David S. Alberts, Franco M. Muggia, James Carmichael, Eric P. Winer, Mohammad Jahanzeb, Alan P. Venook, Keith M. Skubitz, Edgardo Rivera, Joseph A. Sparano, Nicholas J. Dibella, Simon J. Stewart, John J. Kavanagh, Alberto A. Gabizon, Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials, Seminars in Oncology, 2004, 31, 53

    CrossRef

  84. 84
    Soo Jung Gong, Choon Jo Jin, Sun Young Rha, Hyun Cheol Chung, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines, Cancer Letters, 2004, 214, 2, 215

    CrossRef

  85. 85
    Carlo Leonetti, Marco Scarsella, Sean C. Semple, Agnese Molinari, Carmen D'Angelo, Antonella Stoppacciaro, Annamaria Biroccio, Gabriella Zupi, In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors, International Journal of Cancer, 2004, 110, 5
    Direct Link:
  86. 86
    Klaus Mross, Bernward Niemann, Ulrich Massing, Joachim Drevs, Clemens Unger, Rupinder Bhamra, Christine E. Swenson, Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study, Cancer Chemotherapy and Pharmacology, 2004, 54, 6, 514

    CrossRef

  87. 87
    Nicholas J. Robert, Charles L. Vogel, I. Craig Henderson, Joseph A. Sparano, Melvin R. Moore, Paula Silverman, Beth A. Overmoyer, Charles L. Shapiro, John W. Park, Gail T. Colbern, Eric P. Winer, Alberto A. Gabizon, The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer, Seminars in Oncology, 2004, 31, 106

    CrossRef

  88. 88
    Maria Theodoulou, Andrew D Seidman, Cardiac effects of adjuvant therapy for early breastcancer, Seminars in Oncology, 2003, 30, 6, 730

    CrossRef

  89. 89
    Christine E. Swenson, Lois E. Bolcsak, Gerald Batist, Troy H. Guthrie, Katherine H. Tkaczuk, Harold Boxenbaum, Lauri Welles, Shein-Chung Chow, Rupinder Bhamra, Philip Chaikin, Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer, Anti-Cancer Drugs, 2003, 14, 3, 239

    CrossRef

  90. 90
    Hans Wildiers, Martin S Highley, Ernst A de Bruijn, Allan T van Oosterom, Pharmacology of Anticancer Drugs in the Elderly Population, Clinical Pharmacokinetics, 2003, 42, 14, 1213

    CrossRef

  91. 91
    Kavita Maung, Lori Johnson, Joyce O'shaughnessy, 2001 Highlights from: San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-13, 2001, Focus on Novel Approaches in Breast Cancer, Clinical Breast Cancer, 2002, 3, 1, 21

    CrossRef

  92. 92
    Claudia Langebrake, Dirk Reinhardt, J??rg Ritter, Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy, Drug Safety, 2002, 25, 15, 1057

    CrossRef

  93. 93
    Gerald Batist, Jeremy Barton, Philip Chaikin, Christine Swenson, Lauri Welles, Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy, Expert Opinion on Pharmacotherapy, 2002, 3, 12, 1739

    CrossRef

  94. 94
    Antonio C. Wolff, Systemic therapy, Current Opinion in Oncology, 2002, 14, 6, 600

    CrossRef

  95. 95
    Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer, Different anthracycline derivates for reducing cardiotoxicity in cancer patients, The Cochrane Library,
    Direct Link:
  96. 96
    Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer, Different anthracycline derivates for reducing cardiotoxicity in cancer patients, The Cochrane Library,
    Direct Link:
  97. 97
    Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer, Different anthracycline derivates for reducing cardiotoxicity in cancer patients, The Cochrane Library,
    Direct Link:
View Full Article (HTML) Get PDF (139K)